Mazor Robotics to Report Fourth Quarter and Full Year Financial Results on February 14, 2018
- Conference Call Scheduled for 8:30am EST on Wednesday, February 14th -

CAESAREA, Israel, Jan. 30, 2018 /PRNewswire/ -- Mazor Robotics Ltd. (TASE: MZOR) (NASDAQGM: MZOR), a pioneer and a leader in the field of surgical robotic guidance systems, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2017, before the U.S. markets open on Wednesday, February 14, 2018.

The company will host a conference call to discuss these results on Wednesday, February 14, 2018, at 8:30 AM EST (3:30 PM IST).  Investors within the United States interested in participating are invited to call 800-289-0438.   Participants in Israel can use the toll-free dial-in number 1809 212 883. All other international participants can use the dial-in number +1-323-794-2423.

A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-888-203-1112 and reference the Replay Access Code: 5797376. All international callers can dial +1-719-457-0820, using the same Replay Access Code. To access the webcast, please visit and select 'Investor Relations.' 

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit

U.S. Contacts: EVC Group

Michael Polyviou/Doug Sherk - Investors                                           
732.232.6914; 415.652.9100

SOURCE Mazor Robotics Ltd.

Related Links

Latest Tweet

Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf…
Follow Mazor Robotics on Twitter
©2018 Mazor Robotics. All Rights Reserved. Designed By Medtech Momentum